XI’AN, CHINA--(Marketwired - February 26, 2016) - Skystar Bio-Pharmaceutical Company (OTC PINK: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that The Nasdaq Stock Market (“Nasdaq”) filed a Form 25 to complete the Company’s delisting. The Company will be delisted from Nasdaq on March 4, 2016.
The Company previously announced that, on December 17, 2015, the Company received notification from Nasdaq that a Nasdaq hearing panel had decided to delist the Company’s securities from Nasdaq.
Skystar continues to trade on the OTC Pink market under ticker ‘SKBI.’
Delinquent filings
Following the filing and acceptance of its delinquent quarterly and fiscal year end reports with the Securities Exchange Commission pursuant to the Exchange Act of 1934, as amended, Skystar intends to continue to follow applicable Nasdaq listing standards, notwithstanding its delisting.
As of the date of this release, the Company continues to make progress with the completion of its delinquent quarterly and annual reports and intends to file these reports with the SEC following their completed review with Skystar’s external auditors.
About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar’s distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.
Safe Harbor Statements
When used in this release, the words “intends,” “believes,” “anticipated” and “expects” and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the Company’s ability to complete its IgG kit effort as well as other related efforts at the Huxian facilities, the Company’s ability to timely, effectively and accurately assess the efficacy and commercial potential of any technologies that may results from such R&D efforts, the Company’s ability to timely and effectively commercialize any such technologies. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact:
Skystar Bio-Pharmaceutical Company
Scott Cramer
Director - Corporate Development & U.S. Representative
(407) 645-4433
